Tigecycline: Alone or in combination?

References

• Petersen PJ, Jacobus N, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738–44.
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, et al. Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162–72.
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699–709.
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834–44.
   PubMed Web of Science ®Google Scholar
• Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110–6.
   PubMed Web of Science ®Google Scholar
• He F, Fu Y, Chen Q, et al. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-Producing klebsiella pneumoniae. PLoS One 2015;10:e0119064.
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009;58:273–84.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vardakas KZ, Tsiveriotis KP, et al. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014;44:1–7.
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220–9.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27.
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607–15.
   PubMed Web of Science ®Google Scholar
• Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011;70:380–6.
   PubMed Web of Science ®Google Scholar
• Ozbek B, Otuk G. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units. Int J Antimicrob Agents 2010;36:191–2.
   PubMed Web of Science ®Google Scholar
• Hagihara M, Housman ST, Nicolau DP, et al. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2014;58:874–9.
   PubMed Web of Science ®Google Scholar
• Lim TP, Tan TY, Lee W, et al. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 2011;6:e18485.
   PubMed Web of Science ®Google Scholar
• Peck KR, Kim MJ, Choi JY, et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J Med Microbiol 2012;61:353–60.
   PubMed Web of Science ®Google Scholar
• Dizbay M, Tozlu DK, Cirak MY, et al. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 2010;63:51–3.
   PubMed Web of Science ®Google Scholar
• Mutlu Yilmaz E, Sunbul M, Aksoy A, et al. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2012;40:332–6.
   PubMed Web of Science ®Google Scholar
• Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012;40:983–7.
   PubMed Web of Science ®Google Scholar
• Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014;33:1311–22.
   PubMed Web of Science ®Google Scholar
• Lim TP, Tan TY, Lee W, et al. In vitro activity of various combinations of antimicrobials against carbapenem-resistant Acinetobacter species in Singapore. J Antibiot (Tokyo) 2009;62:675–9.
   PubMed Web of Science ®Google Scholar
• Dong X, Chen F, Zhang Y, et al. In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J Antibiot (Tokyo) 2014;67:677–80.
   PubMed Web of Science ®Google Scholar
• Deveci A, Coban AY, Acicbe O, et al. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J Chemother 2012;24:247–52.
   PubMed Web of Science ®Google Scholar
• Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. J Chemother 2015;27:271–6.
   PubMed Web of Science ®Google Scholar
• Sopirala MM, Mangino JE, Gebreyes WA, et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:4678–83.
   PubMed Web of Science ®Google Scholar
• Principe L, D'Arezzo S, Capone A, Petrosillo N, et al. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009;8:18.
   PubMed Web of Science ®Google Scholar
• Principe L, Capone A, Mazzarelli A, et al. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection. Microb Drug Resist 2013;19:407–14.
   PubMed Web of Science ®Google Scholar
• Candel FJ, Calvo N, Head J, et al. A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects. Rev Esp Quimioter 2010;23:103–8.
   PubMed Web of Science ®Google Scholar
• Taccone FS, Rodriguez-Villalobos H, De Backer D, et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006;25:257–60.
   PubMed Web of Science ®Google Scholar
• Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis 2010;14(Suppl 3):e224–6.
   PubMed Web of Science ®Google Scholar
• Ozbek B, Mataraci E. In vitro effectiveness of colistin, tigecycline and levofloxacin alone and combined with clarithromycin and/or heparin as lock solutions against embedded Acinetobacter baumannii strains. J Antimicrob Chemother 2013;68:827–30.
   PubMed Web of Science ®Google Scholar
• Betts JW, Phee LM, Hornsey M, et al. In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2014;58:3541–6.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lombardo D, Lewis RE, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 2014;69:1856–65.
   PubMed Web of Science ®Google Scholar
• Ku YH, Lee MF, Chuang YC, et al. In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum beta-lactamases. J Microbiol Immunol Infect 2015;48:699–702.
   PubMedGoogle Scholar
• Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010;48:3558–62.
   PubMed Web of Science ®Google Scholar
• Di Carlo P, Pantuso G, Cusimano A, et al. Two cases of monomicrobial intraabdominal abscesses due to KPC–3 Klebsiella pneumoniae ST258 clone. BMC Gastroenterol 2011;11:103.
   PubMed Web of Science ®Google Scholar
• Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013;56:697–700.
   PubMed Web of Science ®Google Scholar
• Di Carlo P, Gulotta G, Casuccio A, et al. KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol 2013;13:13.
   PubMed Web of Science ®Google Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014;20:O117–23.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Kelesidis T, Dien Bard J, et al. Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J Med Microbiol 2010;59:1383–6.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mendler MH, Hemming AW, et al. High-dose tigecycline and colistin for successful treatment of disseminated carbapenem-resistant Klebsiella pneumoniae infection in a liver transplant recipient. BMJ Case Rep 2014.
   PubMedGoogle Scholar
• Yim H, Woo H, Song W, et al. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Ann Clin Lab Sci 2011;41:39–43.
   PubMed Web of Science ®Google Scholar
• Wiskirchen DE, Koomanachai P, Nicasio AM, et al. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011;55:1420–7.
   PubMed Web of Science ®Google Scholar
• Vouillamoz J, Moreillon P, Giddey M, et al. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 2008;61:371–4.
   PubMed Web of Science ®Google Scholar
• Michail G, Labrou M, Pitiriga V, et al. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 2013;57:6028–33.
   PubMed Web of Science ®Google Scholar
• Silvestri C, Cirioni O, Arzeni D, et al. In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection. Eur J Clin Microbiol Infect Dis 2012;31:1759–64.
   PubMed Web of Science ®Google Scholar
• Minardi D, Cirioni O, Ghiselli R, et al. Efficacy of tigecycline and rifampin alone and in combination against Enterococcus faecalis biofilm infection in a rat model of ureteral stent. J Surg Res 2012;176:1–6.
   PubMed Web of Science ®Google Scholar
• Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343–4.
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009;43:2108–12.
   PubMed Web of Science ®Google Scholar
• Tang HJ, Chen CC, Zhang CC, et al. In vitro efficacy of fosfomycin-based combinations against clinical vancomycin-resistant Enterococcus isolates. Diagn Microbiol Infect Dis 2013;77:254–7.
   PubMed Web of Science ®Google Scholar
• Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;22:1517–23.
   PubMed Web of Science ®Google Scholar
• Pontikis K, Pefanis A, Tsaganos T, et al. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium. Antimicrob Agents Chemother 2013;57:3392–4.
   PubMed Web of Science ®Google Scholar
• Pettit RK, Weber CA, Lawrence SB, et al. In vivo activity of anprocide alone, and in vitro activity in combination with conventional antibiotics against Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Med Microbiol 2009;58:1203–6.
   PubMed Web of Science ®Google Scholar
• Tang HJ, Chen CC, Cheng KC, et al. In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013;57:5717–20.
   PubMed Web of Science ®Google Scholar
• Szczuka E, Kaznowski A. Antimicrobial activity of tigecycline alone or in combination with rifampin against Staphylococcus epidermidis in biofilm. Folia Microbiol (Praha) 2014;59:283–8.
   PubMed Web of Science ®Google Scholar
• McConeghy KW, LaPlante KL. In vitro activity of tigecycline in combination with gentamicin against biofilm-forming Staphylococcus aureus. Diagn Microbiol Infect Dis 2010;68:1–6.
   PubMed Web of Science ®Google Scholar
• Duez JM, Adochitei A, Pechinot A, et al. In vitro combinations of five intravenous antibiotics with dalfopristin-quinupristin against Staphylococcus aureus in a 3-dimensional model. J Chemother 2008;20:684–9.
   PubMed Web of Science ®Google Scholar
• Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009;63:485–8.
   PubMed Web of Science ®Google Scholar
• Aslam S, Trautner BW, Ramanathan V, et al. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother 2007;51:1556–8.
   PubMed Web of Science ®Google Scholar
• Garrigos C, Murillo O, Euba G, et al. Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus. J Infect 2011;63:229–35.
   PubMed Web of Science ®Google Scholar
• Yin LY, Lazzarini L, Li F, et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005;55:995–1002.
   PubMed Web of Science ®Google Scholar
• Provinciali M, Cirioni O, Orlando F, et al. Vitamin E improves the in vivo efficacy of tigecycline and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus. J Med Microbiol 2011;60:1806–12.
   PubMed Web of Science ®Google Scholar
• Aliskan H, Can F, Demirbilek M, et al. Determining in vitro synergistic activities of tigecycline with several other antibiotics against Brucella melitensis using checkerboard and time-kill assays. J Chemother 2009;21:24–30.
   PubMed Web of Science ®Google Scholar
• Betts JW, Phee LM, Woodford N, et al. Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2014;33:1565–72.
   PubMed Web of Science ®Google Scholar
• Church D, Lloyd T, Peirano G, et al. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis 2013;45:265–70.
   PubMed Web of Science ®Google Scholar
• Singh S, Bouzinbi N, Chaturvedi V, et al. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 2014;20:O1124–27.
   PubMed Web of Science ®Google Scholar
• Huang CW, Chen JH, Hu ST, et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013;41:218–23.
   PubMed Web of Science ®Google Scholar
• Oh CT, Moon C, Park OK, et al. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J Antimicrob Chemother 2014;69:1599–607.
   PubMed Web of Science ®Google Scholar
• Bosse D, Lemire C, Ruel J, et al. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection. Infection 2013;41:579–82.
   PubMed Web of Science ®Google Scholar
• Lao D 2nd, Chiang T, Gomez E. Refractory clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin. Case Rep Med 2012;2012:702910.
   PubMedGoogle Scholar
• El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis 2012;44:228–30.
   PubMed Web of Science ®Google Scholar
• Britt NS, Steed ME, Potter EM, et al. Tigecycline for the treatment of severe and severe complicated clostridium difficile infection. Infect Dis Ther 2014.
   PubMedGoogle Scholar
• Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009;34:8e1–9.
   Web of Science ®Google Scholar
• Lopez-Cortes LE, Cisneros JM, Fernandez-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 2014;69:3119–26.
   PubMed Web of Science ®Google Scholar
• Tangden T, Hickman RA, Forsberg P, Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014;58:1757–62.
   PubMed Web of Science ®Google Scholar
• Demiraslan H, Dinc G, Ahmed SS, et al. Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination. J Chemother 2014;26:276–81.
   PubMed Web of Science ®Google Scholar
• Tang HJ, Chen CC, Cheng KC, et al. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J Antimicrob Chemother 2012;67:944–50.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322–8.
   PubMed Web of Science ®Google Scholar
• Liu B, Bai Y, Liu Y, et al. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. J Chemother 2015;27:271–6.
   PubMed Web of Science ®Google Scholar
• Housman ST, Hagihara M, Nicolau DP, et al. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2013;68:2296–304.
   PubMed Web of Science ®Google Scholar
• Ku YH, Lee MF, Chuang YC, et al. In vitro activity of colistin sulfate against Enterobacteriaceae producing extended-spectrum beta-lactamases. J Microbiol Immunol Infect 2015;48:699–702.
   PubMedGoogle Scholar
• Evren E, Azap OK, Colakoglu S, et al. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 2013;76:335–8.
   PubMed Web of Science ®Google Scholar
• Holmberg A, Rasmussen M. Antibiotic regimens with rifampicin for treatment of Enterococcus faecium in biofilms. Int J Antimicrob Agents 2014;44:78–80.
   PubMed Web of Science ®Google Scholar
• Nuding S, Frasch T, Schaller M, et al. Synergistic effects of antimicrobial peptides and antibiotics against clostridium difficile. Antimicrob Agents Chemother 2014;58:5719–25.
   PubMed Web of Science ®Google Scholar